{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:07:20Z","timestamp":1794049640127,"version":"4.8.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.euroneuro.2017.10.037","type":"journal-article","created":{"date-parts":[[2017,11,10]],"date-time":"2017-11-10T04:46:27Z","timestamp":1510289187000},"page":"1223-1237","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":235,"title":["Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC"],"prefix":"10.1016","volume":"27","author":[{"given":"Tom\u00e1\u0161","family":"Hlo\u017eek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"Uttl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Kade\u0159\u00e1bek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Bal\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Lhotkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel R.","family":"Horsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavl\u00edna","family":"Nov\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"\u0160\u00edchov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krist\u00fdna","family":"\u0160tefkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Tyl\u0161","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kucha\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"P\u00e1len\u00ed\u010dek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2017.10.037_bib1","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1037\/1082-989X.2.4.315","article-title":"Contrast tests of interaction hypotheses","volume":"2","author":"Abelson","year":"1997","journal-title":"Psychol. Methods"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pnpbp.2015.07.001","article-title":"Therapeutic potential of cannabis-related drugs","volume":"64","author":"Alexander","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib3","first-page":"2","article-title":"Time profile of serum THC levels in occasional and chronic marijuana smokers after acute drug use - implication for driving motor vehicles","volume":"59","author":"Bal\u00edkov\u00e1","year":"2014","journal-title":"Soud. Lek."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/npp.2009.184","article-title":"Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology","volume":"35","author":"Bhattacharyya","year":"2010","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0090-9556(25)06664-4","article-title":"Effect of cannabidiol pretreatment on the kinetics of tetrahydrocannabinol metabolites in mouse brain","volume":"23","author":"Bornheim","year":"1995","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib6","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.drugalcdep.2017.01.046","article-title":"Cannabidiol-Delta9-tetrahydrocannabinol interactions on acute pain and locomotor activity","volume":"175","author":"Britch","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib7","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/ajcn\/42.5.1006","article-title":"Effect of diet on gastric secretion","volume":"42","author":"Brooks","year":"1985","journal-title":"Am. J Clin. Nutr."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib8","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/j.pnpbp.2009.08.017","article-title":"Evidence for a potential role for TRPV1 receptors in the dorsolateral periaqueductal gray in the attenuation of the anxiolytic effects of cannabinoids","volume":"33","author":"Campos","year":"2009","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib9","doi-asserted-by":"crossref","first-page":"3364","DOI":"10.1098\/rstb.2011.0389","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib10","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1017\/S1461145712001502","article-title":"The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system","volume":"16","author":"Campos","year":"2013","journal-title":"Int. J Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib11","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.pbb.2010.03.004","article-title":"Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L","volume":"95","author":"El-Alfy","year":"2010","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib12","doi-asserted-by":"crossref","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","article-title":"Fatty acid-binding proteins (FABPs) are intracellular carriers for Delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD)","volume":"290","author":"Elmes","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0269881112460109","article-title":"Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment","volume":"27","author":"Englund","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1177\/0269881115615104","article-title":"The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial","volume":"30","author":"Englund","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.02.696","article-title":"Blood levels do not predict behavioral or physiological effects of Delta(9)-tetrahydrocannabinol in rhesus monkeys with different patterns of exposure","volume":"139","author":"Ginsburg","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib16","article-title":"Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice","volume":"18","author":"Gomes","year":"2014","journal-title":"Int. J Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2017.10.037_bib17","first-page":"102","article-title":"Even High Doses of Oral Cannabidol Do Not Cause THC-Like Effects in Humans: comment on Merrick et al.","volume":"1","author":"Grotenhermen","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbr.2011.03.053","article-title":"Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia","volume":"222","author":"Gururajan","year":"2011","journal-title":"Behav. Brain Res"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1300\/J175v03n04_01","volume":"3","author":"Guy","year":"2004","journal-title":"J. Cannabis Ther."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib20","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: a unified critical inventory","volume":"33","author":"Hanus","year":"2016","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.brainresbull.2016.05.002","article-title":"Detailed pharmacological evaluation of methoxetamine (MXE), a novel psychoactive ketamine analogue-Behavioural, pharmacokinetic and metabolic studies in the Wistar rat","volume":"126","author":"Horsley","year":"2016","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jat\/16.5.276","article-title":"Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana","volume":"16","author":"Huestis","year":"1992","journal-title":"J Anal. Toxicol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","article-title":"Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes","volume":"89","author":"Jiang","year":"2011","journal-title":"Life Sci."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib25","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1373\/clinchem.2010.152439","article-title":"Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration","volume":"57","author":"Karschner","year":"2011","journal-title":"Clin. Chem."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00210-006-0033-x","article-title":"Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors","volume":"372","author":"Kathmann","year":"2006","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib27","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1017\/S1461145713000709","article-title":"Biphasic effects of Delta9-tetrahydrocannabinol on brain stimulation reward and motor activity","volume":"16","author":"Katsidoni","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-2125.2012.04164.x","article-title":"Novel Delta(9) -tetrahydrocannabinol formulation Namisol(R) has beneficial pharmacokinetics and promising pharmacodynamic effects","volume":"74","author":"Klumpers","year":"2012","journal-title":"Br. J Clin. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib29","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib30","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3389\/fphar.2014.00010","article-title":"Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain","volume":"5","author":"Levin","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib31","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib32","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/BF02246292","article-title":"Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats","volume":"119","author":"Lichtman","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib33","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00213-010-1896-6","article-title":"A follow-up study: acute behavioural effects of Delta(9)-THC in female heterozygous neuregulin 1 transmembrane domain mutant mice","volume":"211","author":"Long","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1017\/S1461145709990605","article-title":"A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL\/6JArc mice","volume":"13","author":"Long","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001854","article-title":"Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence","volume":"16","author":"Long","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bbr.2005.07.009","article-title":"The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats","volume":"166","author":"Malone","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.vascn.2014.06.006","article-title":"A vapourized Delta(9)-tetrahydrocannabinol (Delta(9)-THC) delivery system part I: development and validation of a pulmonary cannabinoid route of exposure for experimental pharmacology studies in rodents","volume":"70","author":"Manwell","year":"2014","journal-title":"J. Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pbb.2014.05.010","article-title":"In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Delta9-THC in mice: inhalation versus intraperitoneal injection","volume":"124","author":"Marshell","year":"2014","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1300\/J175v01n03_08","article-title":"Cannabis and cannabis extracts: greater than the sum of their parts?","volume":"1","author":"McPartland","year":"2001","journal-title":"J. Cannabis Ther."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib40","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/bph.12944","article-title":"Are cannabidiol and Delta(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review","volume":"172","author":"McPartland","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrn3811","article-title":"Early phytocannabinoid chemistry to endocannabinoids and beyond","volume":"15","author":"Mechoulam","year":"2014","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib42","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1089\/can.2015.0004","article-title":"Identification of psychoactive degradants of cannabidiol in simulated gastric and physiological fluid","volume":"1","author":"Merrick","year":"2016","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib43","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/npp.2010.58","article-title":"Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis","volume":"35","author":"Morgan","year":"2010","journal-title":"Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib44","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pbb.2006.05.018","article-title":"Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice","volume":"84","author":"Nagai","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib45","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/0006-2952(91)90657-Q","article-title":"Sex difference in the oxidative metabolism of delta 9-tetrahydrocannabinol in the rat","volume":"41","author":"Narimatsu","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib46","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00213-012-2797-7","article-title":"Behavioral, neurochemical and pharmaco-EEG profiles of the psychedelic drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in rats","volume":"225","author":"Palenicek","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.pnpbp.2016.04.004","article-title":"Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): pharmacokinetics, behaviour, thermoregulation and LD50 in rats","volume":"69","author":"Palenicek","year":"2016","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib48","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.3109\/03639041003657295","article-title":"Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers","volume":"36","author":"Paudel","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib49","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s00213-015-3945-7","article-title":"Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine","volume":"232","author":"Pedrazzi","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fphar.2016.00303","article-title":"Cannabidiol, among other cannabinoid drugs, modulates prepulse inhibition of startle in the SHR animal model: implications for schizophrenia pharmacotherapy","volume":"7","author":"Peres","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib51","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cpt197314148","article-title":"Pharmacology of orally administered 9 -tetrahydrocannabinol","volume":"14","author":"Perez-Reyes","year":"1973","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3109\/15563657308990520","article-title":"Toxicology of marijuana: conditions for conversion of cannabidiol to THC upon smoking","volume":"6","author":"Quarles","year":"1973","journal-title":"Clin. Toxicol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib54","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/S0022-3565(24)35376-5","article-title":"Carrier-mediated uptake of the endogenous cannabinoid anandamide in RBL-2H3 cells","volume":"292","author":"Rakhshan","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib55","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0006-2952(01)00616-5","article-title":"Cannabinoid-induced alterations in brain disposition of drugs of abuse","volume":"61","author":"Reid","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2016.12.004","article-title":"Cannabidiol Claims and Misconceptions","author":"Russo","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib57","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib58","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.schres.2011.04.017","article-title":"Cannabis with high cannabidiol content is associated with fewer psychotic experiences","volume":"130","author":"Schubart","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.euroneuro.2013.11.002","article-title":"Cannabidiol as a potential treatment for psychosis","volume":"24","author":"Schubart","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.20088","article-title":"Dose and behavioral context dependent inhibition of movement and basal ganglia neural activity by Delta-9-tetrahydrocannabinol during spontaneous and treadmill locomotion tasks in rats","volume":"55","author":"Shi","year":"2005","journal-title":"Synapse"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1211\/0022357022791","article-title":"Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol","volume":"56","author":"Stinchcomb","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib62","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0022-3565(24)37365-3","article-title":"Comparative receptor binding analyses of cannabinoid agonists and antagonists","volume":"285","author":"Thomas","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib63","article-title":"Interactions between cannabidiol and Delta9-THC following acute and repeated dosing: rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway","author":"Todd","year":"2016","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib64","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.euroneuro.2014.04.003","article-title":"Repeated but not acute treatment with (9)-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D(2)\/(3) receptor antagonist haloperidol","volume":"24","author":"Tournier","year":"2014","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib65","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s00213-006-0356-9","article-title":"Interactions between THC and cannabidiol in mouse models of cannabinoid activity","volume":"186","author":"Varvel","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib66","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1248\/bpb.19.1109","article-title":"Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids","volume":"19","author":"Watanabe","year":"1996","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11419-007-0021-y","article-title":"Conversion of cannabidiol to \u03949-tetrahydrocannabinol and related cannabinoids in artificial gastric juice, and their pharmacological effects in mice","volume":"25","author":"Watanabe","year":"2007","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib68","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1001\/jama.2015.6358","article-title":"Cannabinoids for medical use: a systematic review and meta-analysis","volume":"313","author":"Whiting","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib69","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neulet.2014.05.057","article-title":"Sex differences in Delta(9)-tetrahydrocannabinol metabolism and in vivo pharmacology following acute and repeated dosing in adolescent rats","volume":"576","author":"Wiley","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib70","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0014-2999(03)01856-9","article-title":"Cannabinoid pharmacological properties common to other centrally acting drugs","volume":"471","author":"Wiley","year":"2003","journal-title":"Eur. J Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00008877-199909000-00008","article-title":"Cannabinoid ligands and their effects on learning and performance in rhesus monkeys","volume":"10","author":"Winsauer","year":"1999","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib72","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3390\/ph5050529","article-title":"Cannabidiol in humans-the quest for therapeutic targets","volume":"5","author":"Zhornitsky","year":"2012","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.euroneuro.2017.10.037_bib73","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.2174\/138161212802884681","article-title":"A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation","volume":"18","author":"Zuardi","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.euroneuro.2017.10.037_bib74","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00213-011-2495-x","article-title":"Interaction between cannabidiol (CBD) and (9)-tetrahydrocannabinol (THC): influence of administration interval and dose ratio between the cannabinoids","volume":"219","author":"Zuardi","year":"2012","journal-title":"Psychopharmacology"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17309835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X17309835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T19:35:33Z","timestamp":1750966533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X17309835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0924977X17309835"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.10.037","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic and behavioural profile of THC, CBD, and THC+CBD combination after pulmonary, oral, and subcutaneous administration in rats and confirmation of conversion in vivo of CBD to THC","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2017.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}